<DOC>
	<DOCNO>NCT00040235</DOCNO>
	<brief_summary>This study determine whether magnesium replacement apheresis decrease side effect donor commonly experience . Apheresis method collect large number certain blood cell , white cell , stem cell , platelet . In procedure , whole blood collect needle arm vein , similar donate blood . The blood separate component centrifugation ( spin ) , require cell extract , rest blood return body , either needle another needle arm . When healthy people donate cell apheresis , blood thinner call citrate add prevent blood clot apheresis machine . Citrate work reduce calcium blood . When blood return donor , citrate machine also return , lower donor 's calcium level . As result , donor often feel tingle around mouth , hand , foot . Some symptom prevent give calcium intravenously ( vein ) procedure . Even add calcium , however , donor still symptom . Magnesium level also lower citrate , know cause symptom . This study examine whether decrease magnesium level also contribute side effect apheresis whether magnesium replacement reduce symptom . Healthy apheresis donor 18 year age old enrol NIH protocol may participate study . Donors undergo apheresis procedure require NIH protocol enrol . Throughout procedure , receive intravenous infusion salt solution may may contain magnesium . Blood sample 5 milliliter ( 1 teaspoon ) take apheresis machine begin end procedure 30- 60-minute interval procedure . No 50 ml ( 3 tablespoon ) take single apheresis . The last sample drawn 60 minute completion apheresis . In addition , donor : - Provide urine sample begin end apheresis procedure . - Donate additional urine sample additional 5 ml blood sample morning apheresis - Describe symptom experience apheresis apheresis nurse</brief_summary>
	<brief_title>Magnesium Effects Apheresis</brief_title>
	<detailed_description>Large volume leukapheresis ( LVL ) increasingly use collect peripheral blood stem cell ( PBSCs ) mononuclear cell ( MNC ) hematopoietic immune reconstitution , recent emphasis increase processing volume . Decreases divalent cation level cause administration citrate anticoagulant LVL associate severe donor reaction , may limit rate blood process . Several donor NIH experience citrate-related hypocalcemic tetany LVL , response develop standard operating procedure routine administration prophylactic intravenous calcium solution longer apheresis procedure . Other center utilized heparin reduce amount citrate return donor , however , expose donor systemic anticoagulation may associate hematoma clump apheresis product . We previously determine citrate administration apheresis result significant excretion calcium magnesium urine procedure , performance prolong repeat LVL cause significant depletion blood calcium magnesium level . Decreases calcium level ameliorate procedure perform prophylactic calcium administration . Our preliminary study also demonstrate ionized magnesium level markedly reduce LVL well plateletpheresis procedure . The clinical impact severe , acute decrease ionized magnesium level healthy apheresis donor clear , however . Since adverse effect relate citrate administration prevent prophylactic calcium administration , unknown aspect remain discomfort may attributable hypomagnesemia . This protocol focus determine contribution acute hypomagnesemia citrate-related symptom large-volume apheresis , establish role indication prophylactic intravenous magnesium replacement set . The study plan consist prospective , randomize , placebo-controlled , double-blind study . Healthy allogeneic donor assign one two treatment group . One group receive intravenous magnesium infusion throughout schedule LVL procedure ; group receive equivalent volume infusion normal saline . Symptoms blood sample obtain apheresis nurse laboratory assay perform associate laboratory investigator , blind fashion .</detailed_description>
	<criteria>INCLUSION Healthy allogeneic subject enrol NIH LVL protocol , approval PI : NHLBI protocols99H0046 , 99H0050 , 99H0064 , 98H0122 , 98H0006 , 97H0202 , 97H0196 , 98H0154 , 01H0162 , 01H0010 , 02H0111 ; NIAID protocols 98I0104 , 01I0013 ; DTM protocols00CC0165 ; NCI protocols00C0119 , 00C0201 , 00C0206 Weight great equal 40 kg Bilateral peripheral venous access Minimum LVL volume 12 liter process ( per subject 's primary protocol ) Hematocrit great equal 35 percent Normal serum electrolyte , calcium magnesium value Normal hepatic kidney function test Able give inform consent Age great 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2004</verification_date>
	<keyword>Leukapheresis</keyword>
	<keyword>Hypomagnesemia</keyword>
	<keyword>Plateletpheresis</keyword>
	<keyword>Hypocalcemia</keyword>
	<keyword>Citrate</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
	<keyword>Normal Control</keyword>
</DOC>